Pharma & Healthcare
Global HIV Antivirals Market Research Report 2026
- Mar 14, 26
- ID: 729625
- Pages: 109
- Figures: 116
- Views: 5
This report delivers a comprehensive overview of the global HIV Antivirals market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding HIV Antivirals. The HIV Antivirals market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global HIV Antivirals market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist HIV Antivirals manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Gilead Sciences
ViiV Healthcare
Johnson & Johnson (Janssen Pharmaceuticals)
Merck & Co.
AbbVie
Bristol-Myers Squibb
Roche
Teva Pharmaceuticals
Segment by Type
Fixed Dose Combinations (FDCs)
Integrase Strand Transfer Inhibitors (lNSTls)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTls)
Entry Inhibitors -CCR5 co-receptor antagonist
Protease Inhibitors (Pls)
Nucleoside Reverse Transcriptase lnhibitors (NRTls)
Others
by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for HIV Antivirals manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines HIV Antivirals sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
The report segments the global HIV Antivirals market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist HIV Antivirals manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Gilead Sciences
ViiV Healthcare
Johnson & Johnson (Janssen Pharmaceuticals)
Merck & Co.
AbbVie
Bristol-Myers Squibb
Roche
Teva Pharmaceuticals
Segment by Type
Fixed Dose Combinations (FDCs)
Integrase Strand Transfer Inhibitors (lNSTls)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTls)
Entry Inhibitors -CCR5 co-receptor antagonist
Protease Inhibitors (Pls)
Nucleoside Reverse Transcriptase lnhibitors (NRTls)
Others
by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for HIV Antivirals manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines HIV Antivirals sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
1 HIV Antivirals Market Overview
1.1 Product Definition
1.2 HIV Antivirals by Type
1.2.1 Global HIV Antivirals Market Value by Type: 2025 vs 2032
1.2.2 Fixed Dose Combinations (FDCs)
1.2.3 Integrase Strand Transfer Inhibitors (lNSTls)
1.2.4 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTls)
1.2.5 Entry Inhibitors -CCR5 co-receptor antagonist
1.2.6 Protease Inhibitors (Pls)
1.2.7 Nucleoside Reverse Transcriptase lnhibitors (NRTls)
1.2.8 Others
1.3 HIV Antivirals by Application
1.3.1 Global HIV Antivirals Market Value by Application: 2025 vs 2032
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Global HIV Antivirals Market Size Estimates and Forecasts
1.4.1 Global HIV Antivirals Revenue 2021–2032
1.4.2 Global HIV Antivirals Sales 2021–2032
1.4.3 Global HIV Antivirals Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 HIV Antivirals Market Competition by Manufacturers
2.1 Global HIV Antivirals Sales Market Share by Manufacturers (2021–2026)
2.2 Global HIV Antivirals Revenue Market Share by Manufacturers (2021–2026)
2.3 Global HIV Antivirals Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of HIV Antivirals, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of HIV Antivirals, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of HIV Antivirals, Product Types and Applications
2.7 Global Key Manufacturers of HIV Antivirals, Date of Entry into the Industry
2.8 Global HIV Antivirals Market Competitive Situation and Trends
2.8.1 Global HIV Antivirals Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global HIV Antivirals Players Market Share by Revenue
2.8.3 Global HIV Antivirals Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global HIV Antivirals Market Scenario by Region
3.1 Global HIV Antivirals Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global HIV Antivirals Sales by Region: 2021–2032
3.2.1 Global HIV Antivirals Sales by Region: 2021–2026
3.2.2 Global HIV Antivirals Sales by Region: 2027–2032
3.3 Global HIV Antivirals Revenue by Region: 2021–2032
3.3.1 Global HIV Antivirals Revenue by Region: 2021–2026
3.3.2 Global HIV Antivirals Revenue by Region: 2027–2032
3.4 North America HIV Antivirals Market Facts & Figures by Country
3.4.1 North America HIV Antivirals Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America HIV Antivirals Sales by Country (2021–2032)
3.4.3 North America HIV Antivirals Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe HIV Antivirals Market Facts & Figures by Country
3.5.1 Europe HIV Antivirals Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe HIV Antivirals Sales by Country (2021–2032)
3.5.3 Europe HIV Antivirals Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific HIV Antivirals Market Facts & Figures by Region
3.6.1 Asia Pacific HIV Antivirals Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific HIV Antivirals Sales by Region (2021–2032)
3.6.3 Asia Pacific HIV Antivirals Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America HIV Antivirals Market Facts & Figures by Country
3.7.1 Latin America HIV Antivirals Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America HIV Antivirals Sales by Country (2021–2032)
3.7.3 Latin America HIV Antivirals Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa HIV Antivirals Market Facts & Figures by Country
3.8.1 Middle East and Africa HIV Antivirals Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa HIV Antivirals Sales by Country (2021–2032)
3.8.3 Middle East and Africa HIV Antivirals Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global HIV Antivirals Sales by Type (2021–2032)
4.1.1 Global HIV Antivirals Sales by Type (2021–2026)
4.1.2 Global HIV Antivirals Sales by Type (2027–2032)
4.1.3 Global HIV Antivirals Sales Market Share by Type (2021–2032)
4.2 Global HIV Antivirals Revenue by Type (2021–2032)
4.2.1 Global HIV Antivirals Revenue by Type (2021–2026)
4.2.2 Global HIV Antivirals Revenue by Type (2027–2032)
4.2.3 Global HIV Antivirals Revenue Market Share by Type (2021–2032)
4.3 Global HIV Antivirals Price by Type (2021–2032)
5 Segment by Application
5.1 Global HIV Antivirals Sales by Application (2021–2032)
5.1.1 Global HIV Antivirals Sales by Application (2021–2026)
5.1.2 Global HIV Antivirals Sales by Application (2027–2032)
5.1.3 Global HIV Antivirals Sales Market Share by Application (2021–2032)
5.2 Global HIV Antivirals Revenue by Application (2021–2032)
5.2.1 Global HIV Antivirals Revenue by Application (2021–2026)
5.2.2 Global HIV Antivirals Revenue by Application (2027–2032)
5.2.3 Global HIV Antivirals Revenue Market Share by Application (2021–2032)
5.3 Global HIV Antivirals Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Gilead Sciences
6.1.1 Gilead Sciences Company Information
6.1.2 Gilead Sciences Description and Business Overview
6.1.3 Gilead Sciences HIV Antivirals Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Gilead Sciences HIV Antivirals Product Portfolio
6.1.5 Gilead Sciences Recent Developments/Updates
6.2 ViiV Healthcare
6.2.1 ViiV Healthcare Company Information
6.2.2 ViiV Healthcare Description and Business Overview
6.2.3 ViiV Healthcare HIV Antivirals Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 ViiV Healthcare HIV Antivirals Product Portfolio
6.2.5 ViiV Healthcare Recent Developments/Updates
6.3 Johnson & Johnson (Janssen Pharmaceuticals)
6.3.1 Johnson & Johnson (Janssen Pharmaceuticals) Company Information
6.3.2 Johnson & Johnson (Janssen Pharmaceuticals) Description and Business Overview
6.3.3 Johnson & Johnson (Janssen Pharmaceuticals) HIV Antivirals Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Johnson & Johnson (Janssen Pharmaceuticals) HIV Antivirals Product Portfolio
6.3.5 Johnson & Johnson (Janssen Pharmaceuticals) Recent Developments/Updates
6.4 Merck & Co.
6.4.1 Merck & Co. Company Information
6.4.2 Merck & Co. Description and Business Overview
6.4.3 Merck & Co. HIV Antivirals Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Merck & Co. HIV Antivirals Product Portfolio
6.4.5 Merck & Co. Recent Developments/Updates
6.5 AbbVie
6.5.1 AbbVie Company Information
6.5.2 AbbVie Description and Business Overview
6.5.3 AbbVie HIV Antivirals Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 AbbVie HIV Antivirals Product Portfolio
6.5.5 AbbVie Recent Developments/Updates
6.6 Bristol-Myers Squibb
6.6.1 Bristol-Myers Squibb Company Information
6.6.2 Bristol-Myers Squibb Description and Business Overview
6.6.3 Bristol-Myers Squibb HIV Antivirals Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Bristol-Myers Squibb HIV Antivirals Product Portfolio
6.6.5 Bristol-Myers Squibb Recent Developments/Updates
6.7 Roche
6.7.1 Roche Company Information
6.7.2 Roche Description and Business Overview
6.7.3 Roche HIV Antivirals Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Roche HIV Antivirals Product Portfolio
6.7.5 Roche Recent Developments/Updates
6.8 Teva Pharmaceuticals
6.8.1 Teva Pharmaceuticals Company Information
6.8.2 Teva Pharmaceuticals Description and Business Overview
6.8.3 Teva Pharmaceuticals HIV Antivirals Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Teva Pharmaceuticals HIV Antivirals Product Portfolio
6.8.5 Teva Pharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 HIV Antivirals Industry Chain Analysis
7.2 HIV Antivirals Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 HIV Antivirals Production Mode & Process Analysis
7.4 HIV Antivirals Sales and Marketing
7.4.1 HIV Antivirals Sales Channels
7.4.2 HIV Antivirals Distributors
7.5 HIV Antivirals Customer Analysis
8 HIV Antivirals Market Dynamics
8.1 HIV Antivirals Industry Trends
8.2 HIV Antivirals Market Drivers
8.3 HIV Antivirals Market Challenges
8.4 HIV Antivirals Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
1.1 Product Definition
1.2 HIV Antivirals by Type
1.2.1 Global HIV Antivirals Market Value by Type: 2025 vs 2032
1.2.2 Fixed Dose Combinations (FDCs)
1.2.3 Integrase Strand Transfer Inhibitors (lNSTls)
1.2.4 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTls)
1.2.5 Entry Inhibitors -CCR5 co-receptor antagonist
1.2.6 Protease Inhibitors (Pls)
1.2.7 Nucleoside Reverse Transcriptase lnhibitors (NRTls)
1.2.8 Others
1.3 HIV Antivirals by Application
1.3.1 Global HIV Antivirals Market Value by Application: 2025 vs 2032
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Global HIV Antivirals Market Size Estimates and Forecasts
1.4.1 Global HIV Antivirals Revenue 2021–2032
1.4.2 Global HIV Antivirals Sales 2021–2032
1.4.3 Global HIV Antivirals Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 HIV Antivirals Market Competition by Manufacturers
2.1 Global HIV Antivirals Sales Market Share by Manufacturers (2021–2026)
2.2 Global HIV Antivirals Revenue Market Share by Manufacturers (2021–2026)
2.3 Global HIV Antivirals Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of HIV Antivirals, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of HIV Antivirals, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of HIV Antivirals, Product Types and Applications
2.7 Global Key Manufacturers of HIV Antivirals, Date of Entry into the Industry
2.8 Global HIV Antivirals Market Competitive Situation and Trends
2.8.1 Global HIV Antivirals Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global HIV Antivirals Players Market Share by Revenue
2.8.3 Global HIV Antivirals Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global HIV Antivirals Market Scenario by Region
3.1 Global HIV Antivirals Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global HIV Antivirals Sales by Region: 2021–2032
3.2.1 Global HIV Antivirals Sales by Region: 2021–2026
3.2.2 Global HIV Antivirals Sales by Region: 2027–2032
3.3 Global HIV Antivirals Revenue by Region: 2021–2032
3.3.1 Global HIV Antivirals Revenue by Region: 2021–2026
3.3.2 Global HIV Antivirals Revenue by Region: 2027–2032
3.4 North America HIV Antivirals Market Facts & Figures by Country
3.4.1 North America HIV Antivirals Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America HIV Antivirals Sales by Country (2021–2032)
3.4.3 North America HIV Antivirals Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe HIV Antivirals Market Facts & Figures by Country
3.5.1 Europe HIV Antivirals Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe HIV Antivirals Sales by Country (2021–2032)
3.5.3 Europe HIV Antivirals Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific HIV Antivirals Market Facts & Figures by Region
3.6.1 Asia Pacific HIV Antivirals Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific HIV Antivirals Sales by Region (2021–2032)
3.6.3 Asia Pacific HIV Antivirals Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America HIV Antivirals Market Facts & Figures by Country
3.7.1 Latin America HIV Antivirals Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America HIV Antivirals Sales by Country (2021–2032)
3.7.3 Latin America HIV Antivirals Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa HIV Antivirals Market Facts & Figures by Country
3.8.1 Middle East and Africa HIV Antivirals Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa HIV Antivirals Sales by Country (2021–2032)
3.8.3 Middle East and Africa HIV Antivirals Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global HIV Antivirals Sales by Type (2021–2032)
4.1.1 Global HIV Antivirals Sales by Type (2021–2026)
4.1.2 Global HIV Antivirals Sales by Type (2027–2032)
4.1.3 Global HIV Antivirals Sales Market Share by Type (2021–2032)
4.2 Global HIV Antivirals Revenue by Type (2021–2032)
4.2.1 Global HIV Antivirals Revenue by Type (2021–2026)
4.2.2 Global HIV Antivirals Revenue by Type (2027–2032)
4.2.3 Global HIV Antivirals Revenue Market Share by Type (2021–2032)
4.3 Global HIV Antivirals Price by Type (2021–2032)
5 Segment by Application
5.1 Global HIV Antivirals Sales by Application (2021–2032)
5.1.1 Global HIV Antivirals Sales by Application (2021–2026)
5.1.2 Global HIV Antivirals Sales by Application (2027–2032)
5.1.3 Global HIV Antivirals Sales Market Share by Application (2021–2032)
5.2 Global HIV Antivirals Revenue by Application (2021–2032)
5.2.1 Global HIV Antivirals Revenue by Application (2021–2026)
5.2.2 Global HIV Antivirals Revenue by Application (2027–2032)
5.2.3 Global HIV Antivirals Revenue Market Share by Application (2021–2032)
5.3 Global HIV Antivirals Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Gilead Sciences
6.1.1 Gilead Sciences Company Information
6.1.2 Gilead Sciences Description and Business Overview
6.1.3 Gilead Sciences HIV Antivirals Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Gilead Sciences HIV Antivirals Product Portfolio
6.1.5 Gilead Sciences Recent Developments/Updates
6.2 ViiV Healthcare
6.2.1 ViiV Healthcare Company Information
6.2.2 ViiV Healthcare Description and Business Overview
6.2.3 ViiV Healthcare HIV Antivirals Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 ViiV Healthcare HIV Antivirals Product Portfolio
6.2.5 ViiV Healthcare Recent Developments/Updates
6.3 Johnson & Johnson (Janssen Pharmaceuticals)
6.3.1 Johnson & Johnson (Janssen Pharmaceuticals) Company Information
6.3.2 Johnson & Johnson (Janssen Pharmaceuticals) Description and Business Overview
6.3.3 Johnson & Johnson (Janssen Pharmaceuticals) HIV Antivirals Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Johnson & Johnson (Janssen Pharmaceuticals) HIV Antivirals Product Portfolio
6.3.5 Johnson & Johnson (Janssen Pharmaceuticals) Recent Developments/Updates
6.4 Merck & Co.
6.4.1 Merck & Co. Company Information
6.4.2 Merck & Co. Description and Business Overview
6.4.3 Merck & Co. HIV Antivirals Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Merck & Co. HIV Antivirals Product Portfolio
6.4.5 Merck & Co. Recent Developments/Updates
6.5 AbbVie
6.5.1 AbbVie Company Information
6.5.2 AbbVie Description and Business Overview
6.5.3 AbbVie HIV Antivirals Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 AbbVie HIV Antivirals Product Portfolio
6.5.5 AbbVie Recent Developments/Updates
6.6 Bristol-Myers Squibb
6.6.1 Bristol-Myers Squibb Company Information
6.6.2 Bristol-Myers Squibb Description and Business Overview
6.6.3 Bristol-Myers Squibb HIV Antivirals Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Bristol-Myers Squibb HIV Antivirals Product Portfolio
6.6.5 Bristol-Myers Squibb Recent Developments/Updates
6.7 Roche
6.7.1 Roche Company Information
6.7.2 Roche Description and Business Overview
6.7.3 Roche HIV Antivirals Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Roche HIV Antivirals Product Portfolio
6.7.5 Roche Recent Developments/Updates
6.8 Teva Pharmaceuticals
6.8.1 Teva Pharmaceuticals Company Information
6.8.2 Teva Pharmaceuticals Description and Business Overview
6.8.3 Teva Pharmaceuticals HIV Antivirals Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Teva Pharmaceuticals HIV Antivirals Product Portfolio
6.8.5 Teva Pharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 HIV Antivirals Industry Chain Analysis
7.2 HIV Antivirals Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 HIV Antivirals Production Mode & Process Analysis
7.4 HIV Antivirals Sales and Marketing
7.4.1 HIV Antivirals Sales Channels
7.4.2 HIV Antivirals Distributors
7.5 HIV Antivirals Customer Analysis
8 HIV Antivirals Market Dynamics
8.1 HIV Antivirals Industry Trends
8.2 HIV Antivirals Market Drivers
8.3 HIV Antivirals Market Challenges
8.4 HIV Antivirals Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global HIV Antivirals Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global HIV Antivirals Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global HIV Antivirals Market Competitive Situation by Manufacturers in 2025
Table 4. Global HIV Antivirals Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global HIV Antivirals Sales Market Share by Manufacturers (2021–2026)
Table 6. Global HIV Antivirals Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global HIV Antivirals Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market HIV Antivirals Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of HIV Antivirals, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of HIV Antivirals, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of HIV Antivirals, Product Types and Applications
Table 12. Global Key Manufacturers of HIV Antivirals, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global HIV Antivirals Companies by Tier (Tier 1, Tier 2, Tier 3), based on HIV Antivirals Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global HIV Antivirals Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global HIV Antivirals Sales by Region (K Units), 2021–2026
Table 18. Global HIV Antivirals Sales Market Share by Region (2021–2026)
Table 19. Global HIV Antivirals Sales by Region (K Units), 2027–2032
Table 20. Global HIV Antivirals Sales Market Share by Region (2027–2032)
Table 21. Global HIV Antivirals Revenue by Region (US$ Million), 2021–2026
Table 22. Global HIV Antivirals Revenue Market Share by Region (2021–2026)
Table 23. Global HIV Antivirals Revenue by Region (US$ Million), 2027–2032
Table 24. Global HIV Antivirals Revenue Market Share by Region (2027–2032)
Table 25. North America HIV Antivirals Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America HIV Antivirals Sales by Country (K Units), 2021–2026
Table 27. North America HIV Antivirals Sales by Country (K Units), 2027–2032
Table 28. North America HIV Antivirals Revenue by Country (US$ Million), 2021–2026
Table 29. North America HIV Antivirals Revenue by Country (US$ Million), 2027–2032
Table 30. Europe HIV Antivirals Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe HIV Antivirals Sales by Country (K Units), 2021–2026
Table 32. Europe HIV Antivirals Sales by Country (K Units), 2027–2032
Table 33. Europe HIV Antivirals Revenue by Country (US$ Million), 2021–2026
Table 34. Europe HIV Antivirals Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific HIV Antivirals Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific HIV Antivirals Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific HIV Antivirals Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific HIV Antivirals Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific HIV Antivirals Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America HIV Antivirals Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America HIV Antivirals Sales by Country (K Units), 2021–2026
Table 42. Latin America HIV Antivirals Sales by Country (K Units), 2027–2032
Table 43. Latin America HIV Antivirals Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America HIV Antivirals Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa HIV Antivirals Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa HIV Antivirals Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa HIV Antivirals Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa HIV Antivirals Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa HIV Antivirals Revenue by Country (US$ Million), 2027–2032
Table 50. Global HIV Antivirals Sales (K Units) by Type (2021–2026)
Table 51. Global HIV Antivirals Sales (K Units) by Type (2027–2032)
Table 52. Global HIV Antivirals Sales Market Share by Type (2021–2026)
Table 53. Global HIV Antivirals Sales Market Share by Type (2027–2032)
Table 54. Global HIV Antivirals Revenue (US$ Million) by Type (2021–2026)
Table 55. Global HIV Antivirals Revenue (US$ Million) by Type (2027–2032)
Table 56. Global HIV Antivirals Revenue Market Share by Type (2021–2026)
Table 57. Global HIV Antivirals Revenue Market Share by Type (2027–2032)
Table 58. Global HIV Antivirals Price (US$/Unit) by Type (2021–2026)
Table 59. Global HIV Antivirals Price (US$/Unit) by Type (2027–2032)
Table 60. Global HIV Antivirals Sales (K Units) by Application (2021–2026)
Table 61. Global HIV Antivirals Sales (K Units) by Application (2027–2032)
Table 62. Global HIV Antivirals Sales Market Share by Application (2021–2026)
Table 63. Global HIV Antivirals Sales Market Share by Application (2027–2032)
Table 64. Global HIV Antivirals Revenue (US$ Million) by Application (2021–2026)
Table 65. Global HIV Antivirals Revenue (US$ Million) by Application (2027–2032)
Table 66. Global HIV Antivirals Revenue Market Share by Application (2021–2026)
Table 67. Global HIV Antivirals Revenue Market Share by Application (2027–2032)
Table 68. Global HIV Antivirals Price (US$/Unit) by Application (2021–2026)
Table 69. Global HIV Antivirals Price (US$/Unit) by Application (2027–2032)
Table 70. Gilead Sciences Company Information
Table 71. Gilead Sciences Description and Business Overview
Table 72. Gilead Sciences HIV Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Gilead Sciences HIV Antivirals Product
Table 74. Gilead Sciences Recent Developments/Updates
Table 75. ViiV Healthcare Company Information
Table 76. ViiV Healthcare Description and Business Overview
Table 77. ViiV Healthcare HIV Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. ViiV Healthcare HIV Antivirals Product
Table 79. ViiV Healthcare Recent Developments/Updates
Table 80. Johnson & Johnson (Janssen Pharmaceuticals) Company Information
Table 81. Johnson & Johnson (Janssen Pharmaceuticals) Description and Business Overview
Table 82. Johnson & Johnson (Janssen Pharmaceuticals) HIV Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Johnson & Johnson (Janssen Pharmaceuticals) HIV Antivirals Product
Table 84. Johnson & Johnson (Janssen Pharmaceuticals) Recent Developments/Updates
Table 85. Merck & Co. Company Information
Table 86. Merck & Co. Description and Business Overview
Table 87. Merck & Co. HIV Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Merck & Co. HIV Antivirals Product
Table 89. Merck & Co. Recent Developments/Updates
Table 90. AbbVie Company Information
Table 91. AbbVie Description and Business Overview
Table 92. AbbVie HIV Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. AbbVie HIV Antivirals Product
Table 94. AbbVie Recent Developments/Updates
Table 95. Bristol-Myers Squibb Company Information
Table 96. Bristol-Myers Squibb Description and Business Overview
Table 97. Bristol-Myers Squibb HIV Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. Bristol-Myers Squibb HIV Antivirals Product
Table 99. Bristol-Myers Squibb Recent Developments/Updates
Table 100. Roche Company Information
Table 101. Roche Description and Business Overview
Table 102. Roche HIV Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. Roche HIV Antivirals Product
Table 104. Roche Recent Developments/Updates
Table 105. Teva Pharmaceuticals Company Information
Table 106. Teva Pharmaceuticals Description and Business Overview
Table 107. Teva Pharmaceuticals HIV Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Teva Pharmaceuticals HIV Antivirals Product
Table 109. Teva Pharmaceuticals Recent Developments/Updates
Table 110. Key Raw Materials Lists
Table 111. Raw Materials Key Suppliers Lists
Table 112. HIV Antivirals Distributors List
Table 113. HIV Antivirals Customers List
Table 114. HIV Antivirals Market Trends
Table 115. HIV Antivirals Market Drivers
Table 116. HIV Antivirals Market Challenges
Table 117. HIV Antivirals Market Restraints
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
Table 121. Authors List of This Report
List of Figures
Figure 1. Product Picture of HIV Antivirals
Figure 2. Global HIV Antivirals Market Value by Type (US$ Million), 2021–2032
Figure 3. Global HIV Antivirals Market Share by Type: 2025 & 2032
Figure 4. Fixed Dose Combinations (FDCs) Product Picture
Figure 5. Integrase Strand Transfer Inhibitors (lNSTls) Product Picture
Figure 6. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTls) Product Picture
Figure 7. Entry Inhibitors -CCR5 co-receptor antagonist Product Picture
Figure 8. Protease Inhibitors (Pls) Product Picture
Figure 9. Nucleoside Reverse Transcriptase lnhibitors (NRTls) Product Picture
Figure 10. Others Product Picture
Figure 11. Global HIV Antivirals Market Value by Application (US$ Million), 2021–2032
Figure 12. Global HIV Antivirals Market Share by Application: 2025 & 2032
Figure 13. Hospital Pharmacies
Figure 14. Retail Pharmacies
Figure 15. Online Pharmacies
Figure 16. Global HIV Antivirals Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 17. Global HIV Antivirals Market Size (US$ Million), 2021–2032
Figure 18. Global HIV Antivirals Sales (K Units), 2021–2032
Figure 19. Global HIV Antivirals Average Price (US$/Unit), 2021–2032
Figure 20. HIV Antivirals Report Years Considered
Figure 21. HIV Antivirals Sales Share by Manufacturers in 2025
Figure 22. Global HIV Antivirals Revenue Share by Manufacturers in 2025
Figure 23. Top 5 and Top 10 Global HIV Antivirals Players: Market Share by Revenue in HIV Antivirals in 2025
Figure 24. HIV Antivirals Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 25. Global HIV Antivirals Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 26. North America HIV Antivirals Sales Market Share by Country (2021–2032)
Figure 27. North America HIV Antivirals Revenue Market Share by Country (2021–2032)
Figure 28. United States HIV Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. Canada HIV Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. Europe HIV Antivirals Sales Market Share by Country (2021–2032)
Figure 31. Europe HIV Antivirals Revenue Market Share by Country (2021–2032)
Figure 32. Germany HIV Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. France HIV Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. U.K. HIV Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Italy HIV Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. Russia HIV Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. Asia Pacific HIV Antivirals Sales Market Share by Region (2021–2032)
Figure 38. Asia Pacific HIV Antivirals Revenue Market Share by Region (2021–2032)
Figure 39. China HIV Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Japan HIV Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. South Korea HIV Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. India HIV Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Australia HIV Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. China Taiwan HIV Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Southeast Asia HIV Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Latin America HIV Antivirals Sales Market Share by Country (2021–2032)
Figure 47. Latin America HIV Antivirals Revenue Market Share by Country (2021–2032)
Figure 48. Mexico HIV Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Brazil HIV Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Argentina HIV Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. Colombia HIV Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Middle East and Africa HIV Antivirals Sales Market Share by Country (2021–2032)
Figure 53. Middle East and Africa HIV Antivirals Revenue Market Share by Country (2021–2032)
Figure 54. Turkey HIV Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 55. Saudi Arabia HIV Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 56. UAE HIV Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 57. Global Sales Market Share of HIV Antivirals by Type (2021–2032)
Figure 58. Global Revenue Market Share of HIV Antivirals by Type (2021–2032)
Figure 59. Global HIV Antivirals Price (US$/Unit) by Type (2021–2032)
Figure 60. Global Sales Market Share of HIV Antivirals by Application (2021–2032)
Figure 61. Global Revenue Market Share of HIV Antivirals by Application (2021–2032)
Figure 62. Global HIV Antivirals Price (US$/Unit) by Application (2021–2032)
Figure 63. HIV Antivirals Value Chain
Figure 64. Channels of Distribution (Direct Vs Distribution)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Table 1. Global HIV Antivirals Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global HIV Antivirals Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global HIV Antivirals Market Competitive Situation by Manufacturers in 2025
Table 4. Global HIV Antivirals Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global HIV Antivirals Sales Market Share by Manufacturers (2021–2026)
Table 6. Global HIV Antivirals Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global HIV Antivirals Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market HIV Antivirals Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of HIV Antivirals, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of HIV Antivirals, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of HIV Antivirals, Product Types and Applications
Table 12. Global Key Manufacturers of HIV Antivirals, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global HIV Antivirals Companies by Tier (Tier 1, Tier 2, Tier 3), based on HIV Antivirals Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global HIV Antivirals Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global HIV Antivirals Sales by Region (K Units), 2021–2026
Table 18. Global HIV Antivirals Sales Market Share by Region (2021–2026)
Table 19. Global HIV Antivirals Sales by Region (K Units), 2027–2032
Table 20. Global HIV Antivirals Sales Market Share by Region (2027–2032)
Table 21. Global HIV Antivirals Revenue by Region (US$ Million), 2021–2026
Table 22. Global HIV Antivirals Revenue Market Share by Region (2021–2026)
Table 23. Global HIV Antivirals Revenue by Region (US$ Million), 2027–2032
Table 24. Global HIV Antivirals Revenue Market Share by Region (2027–2032)
Table 25. North America HIV Antivirals Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America HIV Antivirals Sales by Country (K Units), 2021–2026
Table 27. North America HIV Antivirals Sales by Country (K Units), 2027–2032
Table 28. North America HIV Antivirals Revenue by Country (US$ Million), 2021–2026
Table 29. North America HIV Antivirals Revenue by Country (US$ Million), 2027–2032
Table 30. Europe HIV Antivirals Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe HIV Antivirals Sales by Country (K Units), 2021–2026
Table 32. Europe HIV Antivirals Sales by Country (K Units), 2027–2032
Table 33. Europe HIV Antivirals Revenue by Country (US$ Million), 2021–2026
Table 34. Europe HIV Antivirals Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific HIV Antivirals Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific HIV Antivirals Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific HIV Antivirals Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific HIV Antivirals Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific HIV Antivirals Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America HIV Antivirals Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America HIV Antivirals Sales by Country (K Units), 2021–2026
Table 42. Latin America HIV Antivirals Sales by Country (K Units), 2027–2032
Table 43. Latin America HIV Antivirals Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America HIV Antivirals Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa HIV Antivirals Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa HIV Antivirals Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa HIV Antivirals Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa HIV Antivirals Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa HIV Antivirals Revenue by Country (US$ Million), 2027–2032
Table 50. Global HIV Antivirals Sales (K Units) by Type (2021–2026)
Table 51. Global HIV Antivirals Sales (K Units) by Type (2027–2032)
Table 52. Global HIV Antivirals Sales Market Share by Type (2021–2026)
Table 53. Global HIV Antivirals Sales Market Share by Type (2027–2032)
Table 54. Global HIV Antivirals Revenue (US$ Million) by Type (2021–2026)
Table 55. Global HIV Antivirals Revenue (US$ Million) by Type (2027–2032)
Table 56. Global HIV Antivirals Revenue Market Share by Type (2021–2026)
Table 57. Global HIV Antivirals Revenue Market Share by Type (2027–2032)
Table 58. Global HIV Antivirals Price (US$/Unit) by Type (2021–2026)
Table 59. Global HIV Antivirals Price (US$/Unit) by Type (2027–2032)
Table 60. Global HIV Antivirals Sales (K Units) by Application (2021–2026)
Table 61. Global HIV Antivirals Sales (K Units) by Application (2027–2032)
Table 62. Global HIV Antivirals Sales Market Share by Application (2021–2026)
Table 63. Global HIV Antivirals Sales Market Share by Application (2027–2032)
Table 64. Global HIV Antivirals Revenue (US$ Million) by Application (2021–2026)
Table 65. Global HIV Antivirals Revenue (US$ Million) by Application (2027–2032)
Table 66. Global HIV Antivirals Revenue Market Share by Application (2021–2026)
Table 67. Global HIV Antivirals Revenue Market Share by Application (2027–2032)
Table 68. Global HIV Antivirals Price (US$/Unit) by Application (2021–2026)
Table 69. Global HIV Antivirals Price (US$/Unit) by Application (2027–2032)
Table 70. Gilead Sciences Company Information
Table 71. Gilead Sciences Description and Business Overview
Table 72. Gilead Sciences HIV Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Gilead Sciences HIV Antivirals Product
Table 74. Gilead Sciences Recent Developments/Updates
Table 75. ViiV Healthcare Company Information
Table 76. ViiV Healthcare Description and Business Overview
Table 77. ViiV Healthcare HIV Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. ViiV Healthcare HIV Antivirals Product
Table 79. ViiV Healthcare Recent Developments/Updates
Table 80. Johnson & Johnson (Janssen Pharmaceuticals) Company Information
Table 81. Johnson & Johnson (Janssen Pharmaceuticals) Description and Business Overview
Table 82. Johnson & Johnson (Janssen Pharmaceuticals) HIV Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Johnson & Johnson (Janssen Pharmaceuticals) HIV Antivirals Product
Table 84. Johnson & Johnson (Janssen Pharmaceuticals) Recent Developments/Updates
Table 85. Merck & Co. Company Information
Table 86. Merck & Co. Description and Business Overview
Table 87. Merck & Co. HIV Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Merck & Co. HIV Antivirals Product
Table 89. Merck & Co. Recent Developments/Updates
Table 90. AbbVie Company Information
Table 91. AbbVie Description and Business Overview
Table 92. AbbVie HIV Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. AbbVie HIV Antivirals Product
Table 94. AbbVie Recent Developments/Updates
Table 95. Bristol-Myers Squibb Company Information
Table 96. Bristol-Myers Squibb Description and Business Overview
Table 97. Bristol-Myers Squibb HIV Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. Bristol-Myers Squibb HIV Antivirals Product
Table 99. Bristol-Myers Squibb Recent Developments/Updates
Table 100. Roche Company Information
Table 101. Roche Description and Business Overview
Table 102. Roche HIV Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. Roche HIV Antivirals Product
Table 104. Roche Recent Developments/Updates
Table 105. Teva Pharmaceuticals Company Information
Table 106. Teva Pharmaceuticals Description and Business Overview
Table 107. Teva Pharmaceuticals HIV Antivirals Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Teva Pharmaceuticals HIV Antivirals Product
Table 109. Teva Pharmaceuticals Recent Developments/Updates
Table 110. Key Raw Materials Lists
Table 111. Raw Materials Key Suppliers Lists
Table 112. HIV Antivirals Distributors List
Table 113. HIV Antivirals Customers List
Table 114. HIV Antivirals Market Trends
Table 115. HIV Antivirals Market Drivers
Table 116. HIV Antivirals Market Challenges
Table 117. HIV Antivirals Market Restraints
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
Table 121. Authors List of This Report
List of Figures
Figure 1. Product Picture of HIV Antivirals
Figure 2. Global HIV Antivirals Market Value by Type (US$ Million), 2021–2032
Figure 3. Global HIV Antivirals Market Share by Type: 2025 & 2032
Figure 4. Fixed Dose Combinations (FDCs) Product Picture
Figure 5. Integrase Strand Transfer Inhibitors (lNSTls) Product Picture
Figure 6. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTls) Product Picture
Figure 7. Entry Inhibitors -CCR5 co-receptor antagonist Product Picture
Figure 8. Protease Inhibitors (Pls) Product Picture
Figure 9. Nucleoside Reverse Transcriptase lnhibitors (NRTls) Product Picture
Figure 10. Others Product Picture
Figure 11. Global HIV Antivirals Market Value by Application (US$ Million), 2021–2032
Figure 12. Global HIV Antivirals Market Share by Application: 2025 & 2032
Figure 13. Hospital Pharmacies
Figure 14. Retail Pharmacies
Figure 15. Online Pharmacies
Figure 16. Global HIV Antivirals Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 17. Global HIV Antivirals Market Size (US$ Million), 2021–2032
Figure 18. Global HIV Antivirals Sales (K Units), 2021–2032
Figure 19. Global HIV Antivirals Average Price (US$/Unit), 2021–2032
Figure 20. HIV Antivirals Report Years Considered
Figure 21. HIV Antivirals Sales Share by Manufacturers in 2025
Figure 22. Global HIV Antivirals Revenue Share by Manufacturers in 2025
Figure 23. Top 5 and Top 10 Global HIV Antivirals Players: Market Share by Revenue in HIV Antivirals in 2025
Figure 24. HIV Antivirals Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 25. Global HIV Antivirals Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 26. North America HIV Antivirals Sales Market Share by Country (2021–2032)
Figure 27. North America HIV Antivirals Revenue Market Share by Country (2021–2032)
Figure 28. United States HIV Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. Canada HIV Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. Europe HIV Antivirals Sales Market Share by Country (2021–2032)
Figure 31. Europe HIV Antivirals Revenue Market Share by Country (2021–2032)
Figure 32. Germany HIV Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. France HIV Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. U.K. HIV Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Italy HIV Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. Russia HIV Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. Asia Pacific HIV Antivirals Sales Market Share by Region (2021–2032)
Figure 38. Asia Pacific HIV Antivirals Revenue Market Share by Region (2021–2032)
Figure 39. China HIV Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Japan HIV Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. South Korea HIV Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. India HIV Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Australia HIV Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. China Taiwan HIV Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Southeast Asia HIV Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Latin America HIV Antivirals Sales Market Share by Country (2021–2032)
Figure 47. Latin America HIV Antivirals Revenue Market Share by Country (2021–2032)
Figure 48. Mexico HIV Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Brazil HIV Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Argentina HIV Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. Colombia HIV Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Middle East and Africa HIV Antivirals Sales Market Share by Country (2021–2032)
Figure 53. Middle East and Africa HIV Antivirals Revenue Market Share by Country (2021–2032)
Figure 54. Turkey HIV Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 55. Saudi Arabia HIV Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 56. UAE HIV Antivirals Revenue Growth Rate (US$ Million), 2021–2032
Figure 57. Global Sales Market Share of HIV Antivirals by Type (2021–2032)
Figure 58. Global Revenue Market Share of HIV Antivirals by Type (2021–2032)
Figure 59. Global HIV Antivirals Price (US$/Unit) by Type (2021–2032)
Figure 60. Global Sales Market Share of HIV Antivirals by Application (2021–2032)
Figure 61. Global Revenue Market Share of HIV Antivirals by Application (2021–2032)
Figure 62. Global HIV Antivirals Price (US$/Unit) by Application (2021–2032)
Figure 63. HIV Antivirals Value Chain
Figure 64. Channels of Distribution (Direct Vs Distribution)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Smart Grid Digital Substation Market Research Report 2026
Mar 17, 26
Global Photovoltaic Molded Case Circuit Breaker Market Research Report 2026
Mar 17, 26
Global Roll-Roll Automobile Business Market Research Report 2026
Mar 17, 26
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232